What cost-effectiveness demands and market access challenges will novel antibiotics for mdr gnps approved via the streamlined lpad pathway face?

May 1, 2015, 00:00
10.1016/j.jval.2015.03.1414
https://www.valueinhealthjournal.com/article/S1098-3015(15)01471-0/fulltext
Title : What cost-effectiveness demands and market access challenges will novel antibiotics for mdr gnps approved via the streamlined lpad pathway face?
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)01471-0&doi=10.1016/j.jval.2015.03.1414
First page : A243
Section Title : Infection
Open access? : No
Section Order : 880
Categories :
Tags :
Regions :
ViH Article Tags :